Welcome to our dedicated page for Tactile Systems Technology news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems Technology stock.
Tactile Systems Technology, Inc., trading under the symbol TCMD, is a prominent player in the medical technology space, headquartered in Minneapolis, Minnesota. The company specializes in developing innovative medical devices aimed at treating chronic diseases, particularly focusing on conditions like lymphedema and venous ulcers.
As a leader in the field, Tactile Medical's core business revolves around its proprietary platform, including the Flexitouch System—an advanced home-based therapy device designed to help lymphedema patients manage their condition effectively. Additionally, the company offers the Entre System, another home solution for patients suffering from chronic swelling, and the Actitouch System for those with chronic venous insufficiency, which can be worn throughout the day.
Tactile Medical is committed to enhancing the quality of life for patients with chronic swelling by advocating for better patient access and delivering exceptional care through their direct national network. This network includes product specialists, trainers, reimbursement experts, patient advocates, and clinical staff, serving tens of thousands of patients across the United States.
In recent financial updates, the company reported a significant improvement in its fiscal health. For the full year ending 2023, Tactile Medical recorded a net income of $28.5 million, or $1.23 per diluted share, a notable turnaround from a net loss of $17.9 million the previous year. Non-GAAP net income also saw a remarkable rise to $29.5 million from a previous net loss of $3.6 million. Adjusted EBITDA for the year was $29.7 million, compared to $18.3 million in 2022, reflecting substantial growth and profitability.
Looking ahead, Tactile Medical has reaffirmed its optimistic outlook for 2024. The company continues to innovate under the leadership of Sheri Dodd, the newly appointed CEO, who brings extensive experience from her previous roles at Medtronic and other leading healthcare organizations. The company is poised for continued growth, backed by a robust financial position and a dedicated leadership team.
Tactile Medical (Nasdaq: TCMD) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace from December 3rd-5th. The company's management will engage in a fireside chat on December 3rd at 10:00 a.m. Central Time.
The event will be accessible via live audio webcast in the 'Events & Webcasts' section of Tactile Medical's investor relations website, with replay available post-conference. Tactile Medical specializes in at-home therapies for chronic conditions including lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.
Tactile Medical (TCMD) reported Q3 2024 financial results with total revenue increasing 5% year-over-year to $73.1 million. Lymphedema product revenue grew 4% and airway clearance product revenue rose 10%. The company reported net income of $5.2 million, down from $22.3 million in Q3 2023, while Adjusted EBITDA improved to $10.7 million from $7.7 million. The company ended Q3 with $82.1 million in cash and announced a $30 million share repurchase program. The company updated its 2024 revenue guidance to $292-295 million, representing 6-8% growth.
Tactile Systems Technology, Inc. (Nasdaq: TCMD), operating as Tactile Medical, has announced the release date for its third quarter fiscal year 2024 financial results. The results will be disclosed after market close on Monday, November 4, 2024. Following the release, management will host a conference call with a Q&A session at 5:00 p.m. Eastern Time on the same day.
Interested participants can dial 877-407-3088 (201-389-0927 for international callers) and use the access code 13748661. A live webcast will be available on the company's investor relations website. For those unable to attend, a replay will be accessible for two weeks.
Tactile Medical specializes in at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, aiming to improve patients' quality of life and reduce overall healthcare costs.
Tactile Medical (Nasdaq: TCMD) has launched Nimbl, its next-generation pneumatic compression platform, for treating upper extremity lymphedema across the United States. Nimbl, which received FDA 510(k) clearance in June 2024 and CMS PDAC approval in September 2024, is 68% lighter, 40% smaller, and uses 33% less hosing than the company's current basic pneumatic compression device.
The device is indicated for treating both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl offers connectivity to the free Kylee digital application for tracking usage and symptoms. The company plans to expand Nimbl's availability for lower extremity conditions in the coming months.
Tactile Medical (Nasdaq: TCMD) announced positive results from a clinical study on their Flexitouch advanced pneumatic compression device (APCD) for lower extremity lymphedema. The 52-week study, published in the Journal of Vascular Surgery, Venous and Lymphatic Disorders, is the largest U.S. prospective clinical trial on PCDs and lymphedema. Key findings include:
- 92% patient compliance at 8 weeks, 72% at 52 weeks
- 1.4 cm decrease in limb girth
- Cellulitis events reduced from 21.4% to 6.1%
- Skin hyperpigmentation decreased from 75% to 40% of patients
- 6% limb girth reduction at 12 weeks in moderate and severe cases
The study involved 179 Veterans across four VA medical centers, with chronic venous insufficiency being the most common cause of lymphedema (63% of participants). The results demonstrate significant improvements in quality of life, clinical outcomes, and therapy adherence.
Tactile Medical (Nasdaq: TCMD) has received PDAC approval for its Nimbl™ Lymphedema Platform, allowing Medicare billing under HCPCS code E0651. This approval follows the FDA's 510(k) clearance in June 2024. Nimbl, the next-generation pneumatic compression device for lymphedema treatment, offers significant improvements:
- 40% size reduction and 68% weight reduction, enhancing portability
- Integration with the Kylee™ digital app for therapy tracking
- Indicated for lymphedema, chronic edema, venous insufficiency, and wound healing
CEO Sheri Dodd emphasized Nimbl's potential to improve patient acceptance and adherence. The device is set for full commercial launch in the coming weeks, reflecting Tactile Medical's commitment to innovative at-home therapies for chronic conditions.
Tactile Systems Technology (TCMD) reported strong Q2 2024 financial results, with total revenue increasing 7% year-over-year to $73.2 million. Lymphedema product revenue grew 8%, while airway clearance product revenue rose 2%. The company achieved net income of $4.3 million, compared to a net loss in Q2 2023, and Adjusted EBITDA increased 49% to $9.1 million.
Key highlights include:
- Gross margin improved to 73.9% of revenue
- Operating income reached $5.8 million
- 510(k) clearance obtained for Nimbl system, a next-generation lymphedema therapy platform
- Sheri Dodd appointed as new President and CEO
Tactile Medical updated its 2024 financial outlook, now expecting full-year revenue between $293 million and $298 million, representing 7-9% growth year-over-year.
Tactile Systems Technology, Inc. (Nasdaq: TCMD), operating as Tactile Medical, has announced the release date for its second quarter fiscal year 2024 financial results. The results will be disclosed after market close on Monday, August 5, 2024. Following the release, management will host a conference call with a Q&A session at 5:00 p.m. Eastern Time on the same day.
Interested parties can participate in the call by dialing 877-407-3088 (201-389-0927 for international callers) and using the access code 13745955. A live webcast will be available on the company's investor relations website. For those unable to attend, a replay will be accessible for two weeks.
Tactile Medical, symbol TCMD on Nasdaq, announced its participation at the William Blair 44th Annual Growth Stock Conference, taking place from June 4-6, 2024, at the Loews Hotel in Chicago, IL. Management will engage in a fireside chat on June 4 at 9:20 a.m. CT, with a live audio webcast available on the company's investor relations website. The webcast will also be archived for later access. Tactile Medical specializes in at-home therapies for chronic conditions like lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease. The company aims to improve patient outcomes by working with clinicians to expand evidence and awareness, enhance care access, reduce healthcare costs, and improve quality of life.
Tactile Systems Technology, Inc. reported a 4% increase in total revenue to $61.1 million for Q1 2024. The company's lymphedema product revenue grew 5% while airway clearance product revenue decreased by 4%. Net loss was $2.2 million versus $1.9 million in Q1 2023. Adjusted EBITDA rose to $1.0 million from $0.5 million in Q1 2023. The company also completed a clinical trial and published a peer-reviewed study on its products.
FAQ
What is the current stock price of Tactile Systems Technology (TCMD)?
What is the market cap of Tactile Systems Technology (TCMD)?
What does Tactile Systems Technology, Inc. specialize in?
What are some of the key products offered by Tactile Medical?
Where is Tactile Systems Technology, Inc. headquartered?
How has Tactile Medical performed financially in recent years?
Who is the current CEO of Tactile Systems Technology, Inc.?
What is the Flexitouch System?
What recent achievements has Tactile Medical made?
What is the company's outlook for 2024?
How does Tactile Medical support its patients?
What makes Tactile Systems Technology, Inc. a leader in its field?
